No Data
No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Ocumension Therapeutics (01477.HK) will hold a board of directors meeting on August 12 to approve its interim performance.
On July 30th, Gelonhui announced that Eucon Biotechnology-B (01477.HK) will hold a board of directors meeting on August 12, 2024 (Monday) to consider and approve the company's and its affiliates' performance for the mid-term period ending on June 30, 2024, and to consider recommending the payment of interim dividends (if any).
OCUMENSION-B: NOTICE OF BOARD MEETING
Ocumension Therapeutics' (HKG:1477) Stock Price Dropped 9.2% Last Week; Private Equity Firms Would Not Be Happy
Ocumension Therapeutics-B (01477.HK) was subjected to a shareholding reduction of 0.828 million shares by Temasek Holdings (Private) Limited.
According to the latest disclosed equity information of the HKEX, on July 15, 2024, Temasek Holdings (Private) Limited sold 0.828 million shares of Ocumension Therapeutics B (01477.HK) at an average price of HKD 6.9161 per share, involving about HKD 5.7265 million. After the shareholding reduction, the latest shareholding of Temasek Holdings (Private) Limited is 41.4354 million shares, and the shareholding ratio has decreased from 6.09% to 5.97%.
China Accepts Ocumension Therapeutics' Biologic License Application For Eye Drug; Shares Up 3%
No Data